ASCO 2021 – Ferdinandos Skoulidis
Ferdinandos Skoulidis summarizes why the development of KRASG12C targeted therapies failed in the past, relates to new developments in the field of KRASG12C inhibition especially sotorasib and discusses the impact of co-mutations on personalized anticancer therapy.
Here is the full ASCO 2021 report.
More posts
Opening up new vistas for patients with SCLC
Opening up new vistas for patients with SCLC Cisplatin vs. carboplatin in LS-SCL
Enhancing immunosupportive mechanisms via anti-angiogenesis
Enhancing immunosupportive mechanisms via anti-angiogenesis Treatment with anti-a
How does checkpoint inhibition perform in the setting of oncogene-driven lung cancer?
How does checkpoint inhibition perform in the setting of oncogene-driven lung cancer
Immunotherapy: from predictive factors to antibiotics
Immunotherapy: from predictive factors to antibiotics Update of CheckMate 9LA Bas
KRAS, MET, ROS1, HER2: current perspectives
KRAS, MET, ROS1, HER2: current perspectives CodeBreaK100: sotorasib Approximately
EGFR-mutant disease: strategies against sensitizing and resistance-mediating mutations
EGFR-mutant disease: strategies against sensitizing and resistance-mediating mutati
